Support : Dialog Search Aids : Pharmaprojects: Major events in the UP field

Pharmaprojects: Major Events in the Update Information (UP) Field
(DIALOG Files 128, 928; DataStar PHAR)

View the PDF version of this document

• New product — all development compounds appearing for the first time in "Pharmaprojects".
  
  
• New chemical structure — compounds for which a new chemical structure has been identified (highlighted as new), and those where the structure of the lead has changed (highlighted as changed). Please note, chemical structure information does not appear in the print version of "Pharmaprojects".
  
  
• New therapeutic activity — compounds for which a new therapeutic activity has been discovered.
  
  
• New Pharmacological Activity — compounds for which the mechanism of action has been identified for the first time, and compounds for which an additional pharmacological activity has been assigned.
  
  
• New indication — Compounds which are being actively developed for a new specific disease.
  
  
• Licensing opportunities — compounds being offered for licensing by the manufacturer or academic institution concerned. The country or countries for which they are offered are also given and further details may be found in the fulltext.
  
  
• Name granted — compounds which now have been granted an approved name. They are generally known by a research code only up to this point.
  
  
• Compound identified — compounds which were previously identified by a non-specific identifier or a "Pharmaprojects" Number which now have a research code number or some other way to be specifically identified.
  
  
• Discontinued — compounds whose development has been discontinued, along with the highest stage of development reached prior to discontinuation discontinuation and the reason for discontinuation.
  
  
• Suspended — compounds whose development has been temporarily halted, with details of the highest stage reached.
  
  
• Withdrawn — compounds which have been withdrawn post-launch and the reason for their withdrawal.
  
  
• New licensee — additional licensees identified for a particular compound.
  
  
• Licenses discontinued — compounds for which licenses have been discontinued.
  
  
• First launch — compounds which have reached the market for the first time, along with the country and date of first launch. Where the term NAS appears, this means that this is a first launch for a new active substance.
  
  
• Additional launch — all additional launches, giving details of which markets.
  
  
• First registration — compounds which have been approved for the first time worldwide in any market, giving details of the country and date of approval.
  
  
• Additional registration — additional registrations, with countries given.
  
  
• Registration submission — compounds for which first registration submissions have been made, with the country of filing.
  
  
• Orphan drug status granted — drugs which have been granted orphan drug status (a period of marketing exclusivity granted to encourage development of drugs for diseases with a low incidences), listing the country or territory where it is granted and the disease for which it has been granted.
  
  
• Status Changed — highlighting progress of a compound through development.
  
  
• Change in licensee status — all changes in the development status of a compound by a named licensee, where the worldwide status is unchanged.
  
  
• Status reversion — all backwards status changes, where, for example a product returns to Phase III from pre-registration due to a request for further data, or it returns to Phase I from Phase II for reformulation.
  
  
• New patent applications— details of compounds or series of compounds new to "Pharmaprojects" which have been identified from European or International (PCT) patent filings.
  
  
• No development reported — compounds for which there is no evidence of continuing development in the past 14-18 months, and for which the companies involved have declined to comment on whether or not development is discontinued.
  
  
• Development continuing — compounds (previously listed as 'No development reported') for which continuing development has been confirmed.

Last modified on 10 Feb 2004.

top